Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Effect of therapeutic horseback riding on balance and gait of people with multiple sclerosis.
Interferon-beta1b for the treatment of multiple sclerosis.
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity.
Neurorehabilitation Topics in Patients with Multiple Sclerosis: From Outcome Measurements to Rehabilitation Interventions.
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Multiple Sclerosis: An Update.
Myelin injury induces axonal transport impairment but not AD-like pathology in the hippocampus of cuprizone-fed mice.
Hydrogen-rich water improves neurological functional recovery in experimental autoimmune encephalomyelitis mice.
Cervical cord and ventricle affection in neuromyelitis optica.
Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression.
Factors in Patient Empowerment: A Survey of an Online Patient Research Network.
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.
Neurovascular coupling in patients with relapsing-remitting multiple sclerosis.
Developing a Valuation Function for the Preference-Based Multiple Sclerosis Index: Comparison of Standard Gamble and Rating Scale.
TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
Sphingosine-1-Phosphate (S1P) Impacts Presynaptic Functions by Regulating Synapsin I Localization in the Presynaptic Compartment.
Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies.
Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.
Recent insights into the mechanism of action of glatiramer acetate.
Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects.
Central nervous system neuroinflammatory disorders in Asian/Pacific regions.
Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
A Combination Trial of Copaxone plus Estriol in Relapsing Remitting Multiple Sclerosis
The "poison chair" treatment for multiple sclerosis.
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

Pages